COMMUNIQUÉS West-GlobeNewswire

NeuroOne® to Report Second Quarter Fiscal Year 2025 Financial Results on Tuesday, May 13 at 8:30 a.m. Eastern Time
01/05/2025
EDEN PRAIRIE, Minn., May 01, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and [...]
Coast-to-Coast for Cures in support of Breakthrough T1D™ Canada
01/05/2025
Breakthrough T1D Board Member Matt Varey is cycling across Canada in support of type 1 diabetes research TORONTO, May 01, 2025 (GLOBE NEWSWIRE) -- Beginning May 3, 2025, Matt Varey, retired banking executive, Vice Chair [...]
D'un océan à l'autre pour la guérison en appui à Percée DT1(MC) Canada
01/05/2025
Matt Varey, un membre du conseil d’administration de Percée DT1, traverse le Canada à vélo pour appuyer la recherche sur le diabète de type 1 TORONTO, 01 mai 2025 (GLOBE NEWSWIRE) -- À compter du 3 mai, Matt Varey, vice [...]
Oculis to Present its Innovative Late-Stage Pipeline Candidates at Upcoming Ophthalmology Conferences
01/05/2025
ZUG, Switzerland, May 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases [...]
Oculis to Present its Innovative Late-Stage Pipeline Candidates at Upcoming Ophthalmology Conferences
01/05/2025
ZUG, Switzerland, May 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases [...]
AB Science publiera son rapport financier annuel 2024 le vendredi 9 mai 2025
01/05/2025
COMMUNIQUE DE PRESSE AB SCIENCE ANNONCE LA PUBLICATION LE 9 MAI 2025 DE SON RAPPORT FINANCIER ANNUEL 2024 Paris, 1 er mai 2025, 10h AB Science SA (Euronext - FR0010557264 - AB) annonce aujourd'hui le décalage de la [...]
AB Science will publish its 2024 annual financial report on May 9, 2025
01/05/2025
PRESS RELEASE THE COMPANY WILL PUBLISH ITS 2024 ANNUAL FINANCIAL REPORT ON 9 MAY 2025 Paris, May 1 st 2025, 10am CET AB Science SA (Euronext - FR0010557264 - AB) today announced that it has postponed the publication of [...]
PhenQ Reviews: Can This Thermogenic Fat Burner Help You Burn Fat? A Detailed Report By Riti Health Experts
01/05/2025
Read the latest PhenQ review from Riti Health experts. Find out if this popular thermogenic fat burner can boost energy and help you burn stubborn fat. Dover, Delaware, May 01, 2025 (GLOBE NEWSWIRE) -- Fat-burning [...]
Taux de cancer en hausse : les dermatologues tiennent au mois de mai leur campagne nationale sur la prudence au soleil
01/05/2025
L’Association canadienne de dermatologie insiste sur l’importance de se protéger du soleil dans le cadre de sa campagne Prudence sous le soleil du Nord, en mettant l’accent sur l’ombrage, la prévention et la détection [...]
As Skin Cancer Rates Climb, Canadian Dermatologists Champion Sun Safety Nationwide this May
01/05/2025
The Canadian Dermatology Association highlights sun safety in the True North, with a focus on shade, prevention, and early detection. OTTAWA, Ontario, May 01, 2025 (GLOBE NEWSWIRE) -- As the warmth of the sun returns [...]
Biosplice Announces First Patient Dosed in Phase 2 Trial of Cirtuvivint for Advanced Soft-Tissue Sarcomas
01/05/2025
Multicenter study sponsored by SELNET to evaluate cirtuvivint as a second-line monotherapy in selected sarcoma subtypes SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical- [...]
X4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates
01/05/2025
4WARD Phase 3 chronic neutropenia trial in full swing; full enrollment on track for 3Q or 4Q 2025 and top-line data in 2H 2026 Additional analyses of mavorixafor clinical trial data increase confidence in successful [...]
Coloplast A/S Revised guidance for FY 2024/25
01/05/2025
Coloplast revises financial guidance for FY 2024/25 and pre-announces H1 2024/25 key financial figures Coloplast revises the guidance on organic growth and EBIT margin before special items for FY 2024/25. The organic [...]
Teleflex Reports First Quarter Financial Results and Full Year 2025 Outlook
01/05/2025
WAYNE, Pa., May 01, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the first quarter ended March 30, 2025. First quarter financial summary Revenues of $ [...]
Agios Reports First Quarter 2025 Financial Results and Recent Business Highlights
01/05/2025
– U.S. Regulatory Filing Under Active Review for Approval of PYRUKYND ® (mitapivat) in Thalassemia, with PDUFA Goal Date of September 7, 2025 – – Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease On Track, with [...]
FDA Grants OKYO Pharma Fast Track Designation to Urcosimod for Neuropathic Corneal Pain
01/05/2025
LONDON and NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod (formerly called OK-101) to treat NCP, an [...]
Atea Pharmaceuticals to Host Virtual HCV KOL Panel on May 14, 2025
01/05/2025
Panel to Discuss Current Challenges Encountered by Patients with HCV , Results from Atea’s Phase 2 Study of the Regimen of Bemnifosbuvir and Ruzasvir, and What a New Optimized HCV Therapy Could Provide for Prescribers [...]
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2025
01/05/2025
― Enrollment complete in the 12 mg dose cohort (n=16) of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD); initiated the 20 mg dose cohort ― ― On track to provide clinical data from the 12 mg dose [...]
Sol-Gel Announces Reverse Share Split
01/05/2025
NESS ZIONA, Israel, May 01, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (the “Company”) (NASDAQ: SLGL), a clinical-stage dermatology company, today announced a reverse share split (the “Reverse Split”) of the [...]

Pages